MISSION abort after Nexavar fails again in NSCLC
This article was originally published in Scrip
Executive Summary
Bayer and Onyx Pharmaceuticals' targeted anticancer Nexavar (sorafenib) has failed in another Phase III study in non-small cell lung cancer, this time in more advanced patients.